Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS

Philippe Moreau; Ajai Chari; Albert Oriol; Joaquin Martinez-Lopez; Mathias Haenel; Cyrille Touzeau; Sikander Ailawadhi; Britta Besemer; Javier de la Rubia Comos; Cristina Encinas; Maria Victoria Mateos; Hans Salwender; Paula Rodriguez-Otero; Cyrille Hulin; Lionel Karlin; Anna Sureda Balari; Joan Bargay; Lotfi Benboubker; Laura Rosiñol; Stefano Tarantolo; Howard Terebelo; Shiyi Yang; Jianping Wang; Ivo Nnane; Ming Qi; Michele Kosh; Maria Delioukina; Hartmut Goldschmidt

doi:10.1038/s41408-023-00805-x

Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS

Philippe Moreau, Ajai Chari, Albert Oriol, Joaquin Martinez-Lopez, Mathias Haenel, Cyrille Touzeau, Sikander Ailawadhi, Britta Besemer, Javier de la Rubia Comos, Cristina Encinas, Maria Victoria Mateos, Hans Salwender, Paula Rodriguez-Otero, Cyrille Hulin, Lionel Karlin, Anna Sureda Balari, Joan Bargay, Lotfi Benboubker, Laura Rosiñol, Stefano TarantoloHoward Terebelo, Shiyi Yang, Jianping Wang, Ivo Nnane, Ming Qi, Michele Kosh, Maria Delioukina, Hartmut Goldschmidt

Hematology / Oncology / Cancer Center / Breast Clinic

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Article number	33
Journal	Blood cancer journal
Volume	13
Issue number	1
DOIs	https://doi.org/10.1038/s41408-023-00805-x
State	Published - Dec 2023

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1038/s41408-023-00805-x

Cite this

Moreau, P., Chari, A., Oriol, A., Martinez-Lopez, J., Haenel, M., Touzeau, C., Ailawadhi, S., Besemer, B., de la Rubia Comos, J., Encinas, C., Mateos, M. V., Salwender, H., Rodriguez-Otero, P., Hulin, C., Karlin, L., Sureda Balari, A., Bargay, J., Benboubker, L., Rosiñol, L., ... Goldschmidt, H. (2023). Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS. Blood cancer journal, 13(1), Article 33. https://doi.org/10.1038/s41408-023-00805-x

Moreau, P, Chari, A, Oriol, A, Martinez-Lopez, J, Haenel, M, Touzeau, C, Ailawadhi, S, Besemer, B, de la Rubia Comos, J, Encinas, C, Mateos, MV, Salwender, H, Rodriguez-Otero, P, Hulin, C, Karlin, L, Sureda Balari, A, Bargay, J, Benboubker, L, Rosiñol, L, Tarantolo, S, Terebelo, H, Yang, S, Wang, J, Nnane, I, Qi, M, Kosh, M, Delioukina, M & Goldschmidt, H 2023, 'Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS', Blood cancer journal, vol. 13, no. 1, 33. https://doi.org/10.1038/s41408-023-00805-x

@article{22263aa7c56641118107fde03e22aa81,

title = "Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS",

author = "Philippe Moreau and Ajai Chari and Albert Oriol and Joaquin Martinez-Lopez and Mathias Haenel and Cyrille Touzeau and Sikander Ailawadhi and Britta Besemer and {de la Rubia Comos}, Javier and Cristina Encinas and Mateos, {Maria Victoria} and Hans Salwender and Paula Rodriguez-Otero and Cyrille Hulin and Lionel Karlin and {Sureda Balari}, Anna and Joan Bargay and Lotfi Benboubker and Laura Rosi{\~n}ol and Stefano Tarantolo and Howard Terebelo and Shiyi Yang and Jianping Wang and Ivo Nnane and Ming Qi and Michele Kosh and Maria Delioukina and Hartmut Goldschmidt",

note = "Funding Information: These studies (ClinicalTrials.gov Identifiers: NCT03412565 and NCT01998971) were sponsored by Janssen Research & Development, LLC. We thank the patients participating in the PLEIADES and EQUULEUS studies and their families, the staff members at the study sites, the data and safety monitoring committees, and the staff members who were involved in the data collection and analyses. We also thank Amgen for supplying the carfilzomib used in these studies. Medical writing and editorial support were provided by Lisa Shannon, PharmD, of Lumanity Communications Inc., and were funded by Janssen Global Services, LLC. ",

year = "2023",

month = dec,

doi = "10.1038/s41408-023-00805-x",

language = "English (US)",

volume = "13",

journal = "Blood cancer journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma

T2 - final analysis of PLEIADES and EQUULEUS

AU - Moreau, Philippe

AU - Chari, Ajai

AU - Oriol, Albert

AU - Martinez-Lopez, Joaquin

AU - Haenel, Mathias

AU - Touzeau, Cyrille

AU - Ailawadhi, Sikander

AU - Besemer, Britta

AU - de la Rubia Comos, Javier

AU - Encinas, Cristina

AU - Mateos, Maria Victoria

AU - Salwender, Hans

AU - Rodriguez-Otero, Paula

AU - Hulin, Cyrille

AU - Karlin, Lionel

AU - Sureda Balari, Anna

AU - Bargay, Joan

AU - Benboubker, Lotfi

AU - Rosiñol, Laura

AU - Tarantolo, Stefano

AU - Terebelo, Howard

AU - Yang, Shiyi

AU - Wang, Jianping

AU - Nnane, Ivo

AU - Qi, Ming

AU - Kosh, Michele

AU - Delioukina, Maria

AU - Goldschmidt, Hartmut

N1 - Funding Information: These studies (ClinicalTrials.gov Identifiers: NCT03412565 and NCT01998971) were sponsored by Janssen Research & Development, LLC. We thank the patients participating in the PLEIADES and EQUULEUS studies and their families, the staff members at the study sites, the data and safety monitoring committees, and the staff members who were involved in the data collection and analyses. We also thank Amgen for supplying the carfilzomib used in these studies. Medical writing and editorial support were provided by Lisa Shannon, PharmD, of Lumanity Communications Inc., and were funded by Janssen Global Services, LLC.

PY - 2023/12

Y1 - 2023/12

UR - http://www.scopus.com/inward/record.url?scp=85149595607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85149595607&partnerID=8YFLogxK

U2 - 10.1038/s41408-023-00805-x

DO - 10.1038/s41408-023-00805-x

M3 - Letter

C2 - 36882409

AN - SCOPUS:85149595607

SN - 2044-5385

VL - 13

JO - Blood cancer journal

JF - Blood cancer journal

IS - 1

M1 - 33

ER -

Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this